Laurel M. Adams

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 458 citations · Full text

Medicine, Oncology, Pharmacology +17

Rapamycin Prolongs Survival and Arrests Pathophysiologic Changes in Murine Systemic Lupus Erythematosus

Linda M. Warner, Laurel M. Adams, Suren N. Sehgal · Arthritis & Rheumatism · 1994 · 178 citations

Medicine, Immunology, Pharmacology +17

Development and Evaluation of the Activities Measure for Upper Limb Amputees

Linda Resnik, Laurel M. Adams, Matthew Borgia et al. · Archives of Physical Medicine and Rehabilitation · 2012 · 140 citations

Medicine, Physical Medicine, Rehabilitation Medicine +14

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Pamela N. Münster, Rahul Aggarwal, David S. Hong et al. · Clinical Cancer Research · 2015 · 112 citations · Full text

Medicine, Oncology, Pharmacology +15

Suppression of tumor promoter-induced chemiluminescence in mouse epidermal cells by several inhibitors of arachidonic acid metabolism.

Susan M. Fischer, Laurel M. Adams · PubMed · 1985 · 96 citations

Life Sciences, Oncology, Pharmacology +13